On September 24, 2015 NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, reported that it will present early stage clinical data from its indoximod program in melanoma at the European Cancer Congress 2015 (ECC) being held September 25-29 in Vienna, Austria (Press release, NewLink Genetics, SEP 24, 2015, View Source [SID:1234507536]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NewLink Genetics Presentation
Abstract Title: Results of Phase 1b trial of the indoleamine 2,3-dioxygenase (IDO) pathway inhibitor indoximod plus ipilimumab for the treatment of unresectable stage III or IV melanoma
Abstract Number: 514
Time: 4:45 – 6:45 p.m. CET
Date: Saturday, Sept. 26
Location: Hall C, Posterboard #248
Session Title: Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)
Session Type: Poster session